Danaher Surges Into Buy Zone As One Key Division Drives Growth

SUSTAINABILITY: This Mag 7 Member Targets AI Data Centers And All-Renewable ElectricityShares of Danaher (DHR) surged Tuesday, topping a buy zone, after the medical research company beat Wall Street's third-quarter forecasts on the back of its bioprocessing division.Revenue from the biotech division, which includes bioprocessing, grew 6.5% organically, topping guidance for 6% growth, Evercore ISI analyst Vijay Kumar said in a report. Bioprocessing is a key component to developing and manufacturing biologic ...